Protagonist Therapeutics, Inc. (PTGX) Now Covered by BTIG Research

BTIG Research began coverage on shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX) in a research report sent to investors on Friday, July 21st, MarketBeat.com reports. The firm issued a buy rating and a $36.00 price objective on the stock.

Several other equities analysts have also recently weighed in on the stock. BMO Capital Markets raised their price target on shares of Protagonist Therapeutics from $34.00 to $45.00 and gave the company an outperform rating in a research report on Wednesday, May 31st. Zacks Investment Research raised shares of Protagonist Therapeutics from a sell rating to a hold rating in a research report on Wednesday, May 10th. Five equities research analysts have rated the stock with a buy rating, The stock presently has a consensus rating of Buy and a consensus price target of $26.00.

Protagonist Therapeutics (NASDAQ PTGX) traded down 2.78% during mid-day trading on Friday, reaching $11.91. The company had a trading volume of 60,285 shares. Protagonist Therapeutics has a one year low of $8.00 and a one year high of $26.36. The stock has a 50 day moving average price of $12.28 and a 200 day moving average price of $12.30. The company’s market capitalization is $201.30 million.

Protagonist Therapeutics (NASDAQ:PTGX) last issued its earnings results on Tuesday, August 8th. The company reported ($0.89) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.19) by $0.70.

COPYRIGHT VIOLATION WARNING: This article was posted by BNB Daily and is the property of of BNB Daily. If you are reading this article on another publication, it was copied illegally and republished in violation of United States & international trademark & copyright law. The original version of this article can be viewed at https://www.baseball-news-blog.com/2017/08/19/btig-research-begins-coverage-on-protagonist-therapeutics-inc-ptgx-updated-updated-updated.html.

In related news, insider David Y. Liu sold 3,500 shares of the firm’s stock in a transaction dated Monday, July 10th. The shares were sold at an average price of $12.68, for a total value of $44,380.00. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.

A number of institutional investors have recently made changes to their positions in PTGX. California State Teachers Retirement System boosted its position in Protagonist Therapeutics by 8.5% in the second quarter. California State Teachers Retirement System now owns 16,600 shares of the company’s stock valued at $188,000 after buying an additional 1,300 shares in the last quarter. State Street Corp boosted its position in Protagonist Therapeutics by 20.9% in the second quarter. State Street Corp now owns 112,474 shares of the company’s stock valued at $1,270,000 after buying an additional 19,411 shares in the last quarter. Senzar Asset Management LLC purchased a new position in Protagonist Therapeutics during the second quarter valued at approximately $3,094,000. FMR LLC boosted its position in Protagonist Therapeutics by 0.4% in the second quarter. FMR LLC now owns 2,528,462 shares of the company’s stock valued at $28,597,000 after buying an additional 10,264 shares in the last quarter. Finally, Vanguard Group Inc. boosted its position in Protagonist Therapeutics by 3.8% in the second quarter. Vanguard Group Inc. now owns 325,395 shares of the company’s stock valued at $3,680,000 after buying an additional 11,881 shares in the last quarter. 47.46% of the stock is currently owned by institutional investors and hedge funds.

About Protagonist Therapeutics

Protagonist Therapeutics, Inc is a clinical-stage biopharmaceutical company with a peptide technology platform focused on discovering and developing new chemical entities (NECs) to address significant unmet medical needs. The Company’s product pipeline includes PTG-100, PTG-200 and PTG-300. Its primary focus is on developing oral peptide drugs that target biological pathways also targeted by marketed injectable antibody drugs.

Receive News & Ratings for Protagonist Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protagonist Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply